Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus helveticus R0052 + bifidobacterium bifidum R0071 + bifidobacterium infantis R0033
- Development stage
- Unknown
- Lead developer
- Lallemand Health Solutions
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
A multi-strain live probiotic blend consisting of three well-characterized bacterial strains: *Lactobacillus helveticus* R0052, *Bifidobacterium bifidum* R0071, and *Bifidobacterium infantis* R0033. - **Mechanism of action**: These strains modulate the gut microbiota, enhance barrier function, and may regulate immune responses through interaction with intestinal epithelial cells and modulation of local and systemic inflammation[4][3]. - The blend is intended to **support digestive health, immune function, and reduce risk of gastrointestinal infections and some systemic conditions** (such as upper respiratory tract infections in stressed populations)[6]. - Developed and characterized by **Institut Rosell/Lallemand Health Solutions**, these strains have demonstrated safety as a supplement in infants and healthy adults, with GRAS status for use in infant formula and foods[4][3]. - The specific combination is used mainly in **infant formulas and probiotic supplements**[4].
- Other names
- Lactobacillus helveticus Rosell-52Bifidobacterium bifidum Rosell-71Bifidobacterium longum subsp. infantis Rosell-33
Beyond the preview
Go deeper on lactobacillus helveticus R0052 + bifidobacterium bifidum R0071 + bifidobacterium infantis R0033.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus helveticus R0052 + bifidobacterium bifidum R0071 + bifidobacterium infantis R0033.